Your browser doesn't support javascript.
loading
What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer.
LeBlanc, Thomas W; Nickolich, Myles; Rushing, Christel N; Samsa, Gregory P; Locke, Susan C; Abernethy, Amy P.
Afiliación
  • LeBlanc TW; Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA. thomas.leblanc@duke.edu.
  • Nickolich M; Center for Learning Health Care, Duke Clinical Research Institute, Durham, NC, USA. thomas.leblanc@duke.edu.
  • Rushing CN; Department of Medicine, Duke University Medical Center, Durham, NC, USA.
  • Samsa GP; Department of Bioinformatics and Biostatistics, Duke University Medical Center, 2400 Pratt Street, Suite 9000, Durham, NC, 27705, USA.
  • Locke SC; Department of Bioinformatics and Biostatistics, Duke University Medical Center, 2400 Pratt Street, Suite 9000, Durham, NC, 27705, USA.
  • Abernethy AP; Center for Learning Health Care, Duke Clinical Research Institute, Durham, NC, USA.
Support Care Cancer ; 23(12): 3455-63, 2015 Dec.
Article en En | MEDLINE | ID: mdl-25791391
ABSTRACT

PURPOSE:

Patients with advanced non-small cell lung cancer (aNSCLC) face a significant symptom burden. Little is known about the frequency and severity of symptoms over time, so we longitudinally characterized patients' symptoms using the Patient Care Monitor (PCM) version 2.0, an electronic symptom-assessment tool.

METHODS:

Ninety-seven patients with aNSCLC completed the PCM at up to four clinic visits. We analyzed symptom data by incidence, severity, type (functional vs. nonfunctional), proximity to death, and cancer anorexia-cachexia syndrome status (CACS).

RESULTS:

Functional concerns predominated, even in the non-CACS group. Average severity among the top 5 symptoms was worse for functional than nonfunctional items (mean difference 0.62, 95% CI 0.22-1.01, P = 0.003). Severe dyspnea and fatigue were the most prevalent nonfunctional symptoms; moderate/severe dyspnea was reported by at least 29% of patients, and fatigue by over 50%. Depression was reported infrequently, with over half of patients at each visit reporting "none"; moderate or severe depression was reported in only 2.5-9.3 and 3.4-6.2% of patients, respectively. The average number of moderate/severe symptoms increased with proximity to death; 84% reported moderate/severe fatigue in the last 3 months of life, compared to 48% at ≥ 12 months from death (P = 0.007).

CONCLUSIONS:

Patients with aNSCLC face a significant symptom burden, which increases with proximity to death. Symptom type and severity vary by proximity to death, but even patients without overt CACS report significant functional symptoms throughout. We recommend an individualized approach to palliative symptom intervention in advanced lung cancer, based on detailed symptom assessment and tracking.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Evaluación de Síntomas / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Evaluación de Síntomas / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos